Clinical Trial Details

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab versus Paclitaxel in Combination with Subcutaneous Trastuzumab for Stage 1 HER2-positive Breast Cancer - ATEMPT 2.0 (DF/HCC 21-159)

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery.

The name of the study drugs involved are:

  • Trastuzumab-emtansine (T-DM1, Kadcyla)
  • Trastuzumab SC (Herceptin Hylecta)
  • Paclitaxel

Learn More

Principal Investigator(s)

Steve Lo, MD


Dana-Farber Cancer Institute


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.